Latest News
Initial study results of an innovative glaucoma therapy involving eye implants have yielded positive results, and a Phase 2 clinical trial of this exciting potential treatment has begun.
BrightFocus Foundation hosted its 50th Anniversary Celebration and Awards on June 14 at the Smithsonian’s National Museum of the American Indian in Washington, D.C.
In this Issue
- President’s Corner
- New Blood Test Detects Unique Biomarker for Alzheimer’s
- Researcher Spotlight: Kevin Beier, PhD
- Medications That Can Mimic Dementia
- Help Fight Alzheimer’s Through a Donor Advised Fund
On Wednesday, June 14, BrightFocus hosted a bipartisan congressional briefing to highlight the importance of funding and diversity in research to improve health equity and cure brain and vision diseases.
In a finding that raises new questions about the connection between amyloid plaques and Alzheimer’s disease, a Dutch study showed people over age 100 maintained sharp minds despite having brain changes associated with dementia.
Factors that stress the body, such as obesity, can make people more likely to develop macular degeneration when they’re older, even if they’ve returned to a normal weight, new research shows.
The FDA has approved the use of atypical antipsychotic drug Rexulti (brexpiprazole) for treating agitation associated with Alzheimer’s dementia, making it the first FDA-approved treatment for Alzheimer’s agitation in the U.S.
In celebration of its 50th anniversary, BrightFocus Foundation announces the launch of a yearlong campaign and microsite celebrating the international nonprofit’s strides in the fight against Alzheimer’s disease, macular degeneration, and glaucoma and toward greater awareness of the importance of funding brain and vision research and education.
BrightFocus honors the life of Donald L. Price, MD.
A new BrightFocus-funded study suggests that an FDA-approved sleeping pill may slow or stop the progression of Alzheimer’s disease, promising findings that are sparking further investigation.
